Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Leukemia, Plasma Cell 1

Interventions

Dexamethasone 69Lenalidomide 39daratumumab 37Bortezomib 33pomalidomide 30Specimen Handling 27Biopsy 25carfilzomib 24Calcium Dobesilate 23Cyclophosphamide 22Magnetic Resonance Spectroscopy 20dexamethasone acetate 15dexamethasone 21-phosphate 15auricularum 15isatuximab 13fludarabine 12iberdomide 11talquetamab 10belantamab mafodotin 10Melphalan 10selinexor 9X-Rays 8tocilizumab 7fludarabine phosphate 6elotuzumab 6Nuclear Medicine Department, Hospital 5trametinib 4pembrolizumab 4Thalidomide 4Sirolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
High-Throughput Screening Assays × Plasma cell × 30 days × Clear all
NCT03389347 2026-05-08

High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

University of Washington

Phase NA Active not recruiting
40 enrolled 7 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡